Midatech Pharma PLC(MTP)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Midatech Pharma Plc, an open company incorporated by law in England and wales, is a specialist pharmaceutical company focused on the development and commercialization of a wide range of therapeutic products, using its nanometer and sustained-release technologies to enhance the delivery of medicines for major diseases and to meet medical needs. These include diabetes, certain cancers such as liver, pancreas, ovarian and brain (glioblastoma), and neurological/ophthalmic conditions. Midatech’s strategy is to develop partners in rare cancer and other indications, its products within the company, and to accelerate its business growth through strategic acquisitions of complementary products and technologies.

Finance:
Market Cap:16.0M; Shares Outstanding:23.5M; Short Interest: /; Q4 2018(12/31/19): Cash 3.05M. Loss 19.58M/Year

EPS and Sales:
https://finance.yahoo.com/quote/MTP/financials?p=MTP

Date EPS % last year % last quarter
2017.6.30 -0.16 / 78.08%
2017.12.31 -0.4 44.64% -150.00%
2018.6.30 -0.12 25.00% 70.00%
2018.12.31 -0.33 19.35% -175.00%

 

Date Sales % last year % last quarter
2017.6.30 0.62M / -93.13%
2017.12.31 1.29M 474.30% 108.06%
2018.6.30 0.72M 16.07% -44.19%
2018.12.31 2.53M 95.96% 251.39%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=MTP&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/MTP/institutional-ownership/

2020.01.07:
Total institutions: 9,no change
Shares hold: 65.44k shares. no change
shares% hold: 0.28%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/MTP/price-targe

Leave a Reply